Celularity

CELU · NASDAQ

$1.26+$0.10 (+8.62%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.16

CELU analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Feb 2, 2026

Bull case

Celularity Inc. is positioned favorably due to its innovative offerings in off-the-shelf placental-derived cell therapies, which demonstrate potential benefits in soft tissue repair and reconstructive procedures. Notably, the company reported promising data from its PDA-002 product, showcasing a comparable ulcer closure rate of 42.8% at 12 weeks and 53.8% at 20 weeks, which competes effectively against existing FDA-approved treatments. Furthermore, the superior wound healing durability of PDA-002 compared to products like Dermagraft and Dermapace suggests a strong competitive advantage, enhancing the firm's overall market prospects.

Bear case

Celularity Inc faces significant operational risks that could hinder its clinical trials and limit growth in its biobanking and degenerative disease segments, primarily due to potential manufacturing failures. Additionally, the decline in natural killer (NK) cell function with age, which affects cytokine secretion and target cell cytotoxicity, presents a challenge for effective cell therapies aimed at older populations. These fundamental issues, alongside the reliance on the bio-banking segment for the majority of its revenue, contribute to a negative outlook regarding the company's financial stability and growth potential.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.